Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
J Clin Exp Hematop. 2022 Jun 28;62(2):73-78. doi: 10.3960/jslrt.21037. Epub 2022 Apr 27.
Since thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome was first proposed in 2010, there has been considerable progress in this area, particularly regarding its association with idiopathic multicentric Castleman disease (iMCD). TAFRO syndrome is a heterogeneous category with a constellation of symptoms that can develop in the setting of infection, rheumatologic disorder, malignancy, and iMCD. Now, iMCD with TAFRO symptoms is subtyped as iMCD-TAFRO. However, confusion between TAFRO syndrome and iMCD-TAFRO remains. In this article, we discuss the current understanding and future research agenda of TAFRO syndrome and iMCD-TAFRO from the perspective of its new validated international definition.
自 2010 年首次提出血栓性血小板减少性紫癜、全身性水肿、发热、网状纤维纤维化、肾功能不全和器官肿大(TAFRO)综合征以来,该领域取得了相当大的进展,特别是在其与特发性多中心 Castleman 病(iMCD)的相关性方面。TAFRO 综合征是一种具有多种症状的异质性类别,可在感染、风湿性疾病、恶性肿瘤和 iMCD 的背景下发生。现在,具有 TAFRO 症状的 iMCD 被分为 iMCD-TAFRO。然而,TAFRO 综合征和 iMCD-TAFRO 之间仍然存在混淆。本文从其新的经过验证的国际定义的角度讨论了 TAFRO 综合征和 iMCD-TAFRO 的当前认识和未来研究议程。